Synchron's BCI device offers new hope for communication in paralyzed patients
IEEE Spectrum - 20-Dec-2023Non-invasive neural device leads via blood vessel while Neuralink awaits human trials
Join the club for FREE to access the whole archive and other member benefits.
CEO of Synchron, Co-head Vascular Bionics laboratory at the University of Melbourne
Thomas Oxley is the chief executive officer of Synchron and neurointerventionist at Mount Sinai Hospital in New York City. Established the Vascular Bionics laboratory at the University of Melbourne and is currently co-head of this lab. Bachelor's degrees in medical science, medicine and surgery from the University of Monash in Melbourne Australia. Doctorate degrees in philosophy and neuroscience from the University of Melbourne.
See also: Synchron - Brain computer interface company
Details last updated 09-Nov-2020
Non-invasive neural device leads via blood vessel while Neuralink awaits human trials
Stentrode is an endovascular electrode array implanted through the blood vessels
Implantable brain computer interface received FDA approval for human trials in US
A less invasive approach of brain-computer interface than Neuralink